title: Pharmacokinetics of trantinterol and its metabolite in healthy elderly and young subjects.
abstract: OBJECTIVE
  The aim of this study was to investigate and compare the pharmacokinetics of trantinterol and its active amphoteric carboxylic acid metabolite (1-carbonyl trantinterol) between the healthy elderly and young subjects.
  
  
  METHODS
  This was a single-center, open-label, parallel-group study completed by 22 healthy subjects (≥65 years (the elderly group); 18-45 years (the young group); 9 males and 2 females per age group) receiving single oral dose of 50 μg trantinterol tablets. Blood samples were taken at intervals up to 48 hours post-dose.
  
  
  RESULTS
  In both groups, maximum plasma concentration of trantinterol was researched at 0.9 hours, while the tmax of 1-carbonyl trantinterol differed slightly. Trantinterol Cmax and AUClast were higher in the elderly group than the young group, by 27% (90% CI, 0.95-1.69) and 77% (90% CI, 1.25-2.51), respectively. For 1-carbonyl trantinterol, Cmax, and AUClast were also higher, by 36% (90% CI, 1.04-1.78) and 71% (90% CI, 1.27-2.30), respectively, in the elderly group. The CL/F and V/F of trantinterol and 1-carbonyl trantinterol were significantly lower in the elderly group, while t1/2 of both did not show significant differences. CL/F of trantinterol and 1-carbonyl trantinterol were found to significantly correlate inversely with age, and positively with the baseline creatinine clearance.
  
  
  CONCLUSIONS
  A single dose of 50 μg trantinterol was well tolerated. Significant changes in Cmax and AUC of trantinterol and 1-carbony trantinterol were seen in the elderly and may be clinically important.
authors: Jie
authors: J
authors: Huang
authors: Qi
authors: Q
authors: Pei
authors: Hongyi
authors: H
authors: Tan
authors: Hong
authors: H
authors: Yuan
authors: Youli
authors: Y
authors: Lu
authors: Gangyi
authors: G
authors: Liu
authors: Zhijun
authors: Z
authors: Huang
authors: Guoping
authors: G
authors: Yang
mesh_terms: D000328:Adult; D000368:Aged; D019540:Area Under Curve; D002976:Clenbuterol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008297:Male; D055815:Young Adult
chemical_list: C542064:trantinterol; D002976:Clenbuterol